Genzyme pays back $6M jobs incentive

Genzyme, technically falling short of job-creation goals set by Massachusetts in an incentives package, has repaid the state $6 million.

Spokesperson Erin Emlock says in an email the company created about 300 jobs last year. But when it sold its genetic testing business in September, the count fell below the requisite 200 positions.

Mass High Tech reports that the prompt payback was praised by the Massachusetts Life Sciences Center, which provided the package.

Meanwhile, Genzyme is working to complete a new plant in Framingham, west of Boston, expected to come on line later this year. It will be home to Cerezyme and Fabrazyme, the production of which is being transferred out of the company's Allston Landing facility per a consent decree with the FDA.

Genzyme announced last week that it will build an additional manufacturing plant in Geel, Belgium, for the production of Myozyme and Lumizyme for Pompe disease. A ceremony last week marked the start of construction.

The plant will have an 8,000-liter production capacity. Commercial approvals for the site are expected beginning late 2014.

- here's the article
- see the Geel announcement

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.